Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 11 selected

Guidance programme

Showing 51 to 100 of 1239

TitleReference numberPublishedLast updated
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and overTA950
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancerTA951
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatmentsTA947
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatmentsTA948
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal)TA945
Caesarean birthNG192
Devices for remote monitoring of Parkinson's diseaseDG51
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancerTA946
Early and locally advanced breast cancer: diagnosis and managementNG101
Sebelipase alfa for treating Wolman diseaseHST30
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancerTA944
Bipolar disorder: assessment and managementCG185
Targeted-release budesonide for treating primary IgA nephropathyTA937
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)TA940
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)TA941
Empagliflozin for treating chronic kidney diseaseTA942
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetesTA943
Risdiplam for treating spinal muscular atrophyTA755
Cardiovascular disease: risk assessment and reduction, including lipid modificationNG238
Velmanase alfa for treating alpha-mannosidosisHST29
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancerTA939
Acne vulgaris: managementNG198
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)TA938
Secukinumab for treating moderate to severe hidradenitis suppurativaTA935
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)TA936
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)TA933
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptomsTA934
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)TA932
Zanubrutinib for treating chronic lymphocytic leukaemiaTA931
Transient loss of consciousness ('blackouts') in over 16sCG109
Hypertension in adults: diagnosis and managementNG136
Suspected acute respiratory infection in over 16s: assessment at first presentation and initial managementNG237
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatmentsTA930
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancerCG164
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fractionTA929
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodineTA928
Jaundice in newborn babies under 28 daysCG98
Pneumonia in adults: diagnosis and managementCG191
Ranibizumab for treating diabetic macular oedemaTA274
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitableTA917
Tirzepatide for treating type 2 diabetesTA924
Mirikizumab for treating moderately to severely active ulcerative colitisTA925
Baricitinib for treating severe alopecia areataTA926
Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal)TA923
Stroke rehabilitation in adultsNG236
Rimegepant for treating migraineTA919
Tofacitinib for treating active ankylosing spondylitisTA920
Ruxolitinib for treating polycythaemia veraTA921
Daridorexant for treating long-term insomniaTA922
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA927

Results per page

  1. 10
  2. 25
  3. 50
  4. All